BR112014006220A2 - composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica - Google Patents

composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica

Info

Publication number
BR112014006220A2
BR112014006220A2 BR112014006220A BR112014006220A BR112014006220A2 BR 112014006220 A2 BR112014006220 A2 BR 112014006220A2 BR 112014006220 A BR112014006220 A BR 112014006220A BR 112014006220 A BR112014006220 A BR 112014006220A BR 112014006220 A2 BR112014006220 A2 BR 112014006220A2
Authority
BR
Brazil
Prior art keywords
treatment
galacto
alcoholic
compositions
ramnogalacturonate
Prior art date
Application number
BR112014006220A
Other languages
English (en)
Portuguese (pt)
Inventor
A Klyosov Anatole
Zomer Eliezer
G Traber Peter
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Publication of BR112014006220A2 publication Critical patent/BR112014006220A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014006220A 2011-09-16 2012-09-14 composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica BR112014006220A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535655P 2011-09-16 2011-09-16
US201261656288P 2012-06-06 2012-06-06
PCT/US2012/055360 WO2013040324A1 (en) 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
BR112014006220A2 true BR112014006220A2 (pt) 2017-04-11

Family

ID=47883762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006220A BR112014006220A2 (pt) 2011-09-16 2012-09-14 composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica

Country Status (12)

Country Link
US (2) US20130259870A1 (enExample)
EP (1) EP2755480B1 (enExample)
JP (1) JP6185473B2 (enExample)
KR (1) KR101974675B1 (enExample)
CN (1) CN103945695B (enExample)
AU (1) AU2012308491B2 (enExample)
BR (1) BR112014006220A2 (enExample)
CA (1) CA2848711C (enExample)
ES (1) ES2869884T3 (enExample)
IL (1) IL231512B (enExample)
MX (1) MX360979B (enExample)
WO (2) WO2013040324A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2013101314A1 (en) 2011-12-28 2013-07-04 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) * 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌の処置における特異的免疫療法を向上する方法
AU2014321711B2 (en) * 2013-09-19 2019-11-14 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
AR099707A1 (es) * 2014-03-10 2016-08-10 La Jolla Pharma Co Composiciones y métodos para tratar trastornos renales
JP2017525702A (ja) * 2014-08-18 2017-09-07 ファーマジェネシス， インコーポレイテッド ポリガラクツロナンラムノガラクツロナン（ｐｇｒｇ１）組成物
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP6890536B2 (ja) * 2015-03-03 2021-06-18 三菱商事ライフサイエンス株式会社 非アルコール性脂肪肝改善又は予防組成物
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
NZ776616A (en) * 2015-06-30 2024-11-29 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP7086008B2 (ja) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP3463350B1 (en) * 2016-06-03 2023-09-13 ChemoCentryx, Inc. Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US10695363B2 (en) 2017-04-14 2020-06-30 Gelesis Llc Compositions and methods for treating or preventing gut permeability-related disorders
US11576924B2 (en) 2017-05-12 2023-02-14 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019010024A1 (en) * 2017-07-04 2019-01-10 The Regents Of The University Of California METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH INFLAMMATION OF DOOR SPACE OR PERIODAL INFLAMMATION
US11808772B2 (en) * 2017-07-19 2023-11-07 Bio-Rad Europe Gmbh Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
GB201804922D0 (en) * 2018-03-27 2018-05-09 Ucl Business Plc Traatment
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
BR112022022737A2 (pt) * 2020-05-22 2023-01-31 Durect Corp Tratamento de esteatose hepática não alcoólica (ehna)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011285A1 (de) 1990-04-06 1991-10-10 Steigerwald Arzneimittelwerk Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose
US6297229B1 (en) 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US6180139B1 (en) 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
AU4055000A (en) 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US6592910B1 (en) 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
CN1142272C (zh) 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
WO2001056547A2 (en) * 2000-02-04 2001-08-09 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
MXPA04000630A (es) 2001-07-20 2005-02-17 Intermune Inc Metodo para tratar fibrosis del higado.
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
CN102293773A (zh) 2004-02-27 2011-12-28 旭化成制药株式会社 含有苯并硫氮杂卓和苯并虑平化合物的药物
WO2005095463A1 (en) * 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
JP2008105945A (ja) 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
US7897583B2 (en) 2005-05-24 2011-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPRU
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US7897591B2 (en) * 2005-07-28 2011-03-01 Children's Medical Center Corporation Method of treating fatty liver disease
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
AU2007260528A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
KR20100091219A (ko) * 2007-11-30 2010-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 시스테아민 산물을 이용한 비-알코올성 지방성간염(ｎａｓｈ) 치료 방법
KR101516677B1 (ko) * 2008-01-31 2015-05-04 고토부키 세이야쿠 가부시키가이샤 지방성 간 질환의 치료용 의약 조성물
EP2260305A1 (en) 2008-03-27 2010-12-15 INSERM (Institut National de la Santé et de la Recherche Medicale) Methods and kits for determining the occurrence of a liver disease in a subject
US20110082119A1 (en) * 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010058295A2 (en) * 2008-11-18 2010-05-27 Universite D'angers Non-invasive in vitro method for quantifying liver lesions
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2013101314A1 (en) * 2011-12-28 2013-07-04 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases

Also Published As

Publication number Publication date
WO2013040316A1 (en) 2013-03-21
CN103945695B (zh) 2018-04-17
EP2755480A4 (en) 2015-04-29
IL231512B (en) 2019-02-28
US20130259870A1 (en) 2013-10-03
CA2848711C (en) 2019-08-06
EP2755480B1 (en) 2021-03-31
KR20140107180A (ko) 2014-09-04
KR101974675B1 (ko) 2019-05-02
AU2012308491B2 (en) 2016-01-07
AU2012308491A1 (en) 2014-04-03
EP2755480A1 (en) 2014-07-23
WO2013040324A1 (en) 2013-03-21
JP6185473B2 (ja) 2017-08-23
MX2014003213A (es) 2015-05-15
US8658787B2 (en) 2014-02-25
JP2014526513A (ja) 2014-10-06
ES2869884T3 (es) 2021-10-26
MX360979B (es) 2018-11-22
IL231512A0 (en) 2014-04-30
US20130171151A1 (en) 2013-07-04
CN103945695A (zh) 2014-07-23
CA2848711A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014010223A8 (pt) inibidores de reciclagem de ácido de bílis para o tratamento de doenças hepáticas colestáticas pediatras
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112014010228A8 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
BR112014026703A2 (pt) inibidores de dna-pk
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
BR112015021888A2 (pt) inibidores de dna-ik
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015001313A2 (pt) composições de vacina
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112015014367A2 (pt) formulações inibidoras de lfa-1
BR112014019399A2 (pt) métodos de tratamento da fibrose
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112013010367A2 (pt) métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements